@entity1073 ( @entity1073 ) responds poorly to standard chemotherapy regimens used in @entity1893 . As a result, a combination of @entity2101 ( @entity2101 ) with autologous stem cell transplantation (ASCT) is being investigated in @entity1 with @entity1073 . So far, however, there is no evidence for long-term remission -- believed, in part, to be due to contamination of the transfusion product with @entity5 cells. Many ex-vivo purging methods have been developed to remove @entity5 cells, but these are complicated, time-consuming and expensive. This study describes an in vivo purging method using rituximab to produce a @entity5 -free stem cell product for re-infusion following @entity2101 . The regimen is split into a purging phase and a myeloablative phase, which together consist of four-step high-dose sequential chemotherapy (sHDT) and six infusions of rituximab immunotherapy. The sHDT comprises @entity786 , @entity2592 , @entity3601 and @entity2664 plus @entity3601 . There are two separate stem cell harvests and three reinfusions. In a pilot study 28 @entity1 with untreated @entity1073 received standard chemotherapy followed by sHDT with rituximab in vivo purging. Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable @entity1 , 100% lymphoma-negative harvests were achieved following in vivo purging. PCR analyses of the bone marrow following the four-step high-dose regimen with purging and transplantation showed that all @entity1 achieved molecular remission. After a median follow-up of 22 months (range 10-42 months), two @entity1 had died while 26 were alive and disease free. This method allows efficient in vivo purging in the context of an effective chemotherapy regimen and may have a role as first-line therapy in @entity1073 @entity1 who respond poorly to standard treatment.

Rituximab: enhancing stem cell transplantation in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'residual cancer'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside'] @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['HDT', 'high-dose chemotherapy'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['Mantle cell lymphoma', 'MCL'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]
@entity1073 :: (MESH:D020522,Disease) :: ['mantle cell lymphoma']
